| 【Company Research】AK Medical (1789 HK) – Solid growth driven by increasing non-VBP sales |
| 【Company Research】Poly Services (6049 HK) – 1H23 results in line but AR remains a concern |
| 【Sector Research】China Technology – Global fabless/IDM 2Q23 wrap: expect continued inventory correction for non-AI players; All eyes on NVDA 3Q23E guidance |
| 【公司研究】百果园 (2411 HK) – 1H23收入同比+6.4%；9月进港股通 |
| 【Company Research】iQIYI (IQ US) – Prioritizing on long-term subs value |
| 【Company Research】Smoore Int’l (6969 HK) – 1H rev/np -9%/-48%; potential turn-around by 2024 |
| 【Company Research】Glodon (002410 CH) – 1H23 miss amid property sector headwind |
| 【Company Research】Anta Sports (2020 HK) – Costs control and efficiency gains are the keys |
| 【Company Research】Simcere Pharmaceutical (2096 HK) – Innovative drugs contributing majority of sales |
| 【行业研究】中国医药 – 海外CXO 2Q23业绩综述：业绩出现分化；融资复苏尚需时间；需求展望有所改善 |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
